A new test for autism spectrum disorder: Metabolic data from different cell types

Sujata Srikanth; Lauren Cascio; Rini Pauly; Kelly Jones; Skylar Sorrow; Rossana Cubillan; Chin-Fu Chen; Cindy D Skinner; Kevin Champaigne; Roger E Stevenson; Charles E Schwartz; Luigi Boccuto

doi:10.1016/j.dib.2021.107598

A new test for autism spectrum disorder: Metabolic data from different cell types

Data Brief. 2021 Nov 23:39:107598. doi: 10.1016/j.dib.2021.107598. eCollection 2021 Dec.

Authors

Affiliations

¹ Greenwood Genetic Center, 101 Gregor Mendel Circle, Greenwood, SC 29646, USA.
² Circa Bioscience, Greenwood, 113 Gregor Mendel Circle, Greenwood, SC 29646, USA.
³ School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, 508 Edwards Hall, Clemson, SC 29634, USA.

Abstract

Experiments employing the Phenotype Mammalian Microarray (PM-M) technology were performed on lymphoblastoid cell lines (LCLs) from individuals with autism spectrum disorder (ASD) and age-matched controls. We used the custom-made PM-M plate designed to assess differential utilization of the amino acid tryptophan. Multiple parameters such as the sample size, incubation time, and cell concentration have been tested, leading to optimized protocols and minimized background noise by variable selection while controlling for false discoveries. The assay generated data based on the production of nicotinamide adenine dinucleotide (NADH) in the presence of different compounds containing tryptophan and showed clear differences between ASD and control samples.

Keywords: Autism spectrum disorder (ASD); Diagnostic test; Metabolism; Screening test; Tryptophan.